Christopher M Starr sold $659k of MNPR
director at Monopar Therapeutics. 8,400 shares at an average of $78.50, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +15RoleDirector
- +20Trade size$659k at market
- +20Share of holdings soldSold 62% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-032048, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +8,400 | $0.01 | $42 | 13,573 | 8 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -4,631 | $78.09 | $362k | 8,942 | 8 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2,970 | $78.82 | $234k | 5,972 | 8 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -799 | $79.67 | $64k | 5,173 | 8 d ago |
| Oct 1, 2026 | MOption exercise Stock Optionderivative10b5-1 | -8,400 | $0.00 | $0 | 8,400 | 8 d ago |
Related signals
Other insiders at Monopar Therapeutics and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $2.6M 29,056 shares | -23% | |
| 20Weak | Monopar Therapeutics | Raymond Anderson director | $352k 3,142 shares | -37% | |
| 32Weak | Monopar Therapeutics | Kim R Tsuchimoto director | $456k 4,090 shares | -100% | |
| 30Weak | Monopar Therapeutics | Raymond Anderson director | $351k 3,142 shares | -12% | |
| 37Weak | Monopar Therapeutics | Kim R Tsuchimoto director | $456k 4,090 shares | -36% | |
| 0Weak | Monopar Therapeutics | Patrice Rioux other | $111 1 shares | -0% | |
| 48Moderate | MNPRbuy Monopar Therapeutics | Quan Anh Vu Chief Financial Officer | $105k 1,500 shares | - | |
| 40Moderate | MNPRsell Monopar Therapeutics | Arthur J Klausner director | $344k 5,121 shares | -37% | |
| 70Notable | MNPRsell Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $35M 550,229 shares | -67% | |
| 65Notable | Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $672k 16,800 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.